| dbo:abstract |
Copper (64Cu) oxodotreotide or Copper Cu 64 dotatate, sold under the brand name Detectnet, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults. Common side effects include nausea, vomiting and flushing. It was approved for medical use in the United States in September 2020. (en) |
| dbo:alternativeName |
Detectnet (en) |
| dbo:casNumber |
1426155-87-4 |
| dbo:fdaUniiCode |
N3858377KC |
| dbo:inn |
Copper (64Cu) oxodotreotide |
| dbo:kegg |
D11882 |
| dbo:pubchem |
124220636 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Copper_(64Cu)_oxodotreotide.svg?width=300 |
| dbo:wikiPageExternalLink |
https://www.curiumpharma.com/wp-content/uploads/2020/08/SDS-US-copper-Cu-64-dotatate-injection_.pdf https://druginfo.nlm.nih.gov/drugportal/name/copper%20dotatate%20cu-64 |
| dbo:wikiPageID |
65239613 (xsd:integer) |
| dbo:wikiPageLength |
6692 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1120345182 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Somatostatin_receptor dbr:Copper-64 dbc:Copper_complexes dbc:DOTA_(chelator)_derivatives dbc:Radiopharmaceuticals dbc:Orphan_drugs dbr:DOTA-TATE dbr:Food_and_Drug_Administration dbr:Positron_emission_tomography dbr:Intravenous dbr:PET_radiotracer dbr:Neuroendocrine_tumors |
| dbp:atcPrefix |
None (en) |
| dbp:c |
65 (xsd:integer) |
| dbp:casNumber |
1426155 (xsd:integer) |
| dbp:cu |
1 (xsd:integer) |
| dbp:dailymedid |
Detectnet (en) |
| dbp:h |
88 (xsd:integer) |
| dbp:inn |
Copper oxodotreotide (en) |
| dbp:iupacName |
2 (xsd:integer) |
| dbp:kegg |
D11882 (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:n |
14 (xsd:integer) |
| dbp:o |
19 (xsd:integer) |
| dbp:pregnancyUs |
N (en) |
| dbp:pubchem |
124220636 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Intravenous |
| dbp:s |
2 (xsd:integer) |
| dbp:smiles |
CCO.[Cu+2] (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
IJRLLVFQGCCPPI-NVGRTJHCSA-L (en) |
| dbp:tradename |
Detectnet (en) |
| dbp:unii |
N3858377KC (en) |
| dbp:width |
300 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Cite_web dbt:Diagnostic_radiopharmaceuticals dbt:Infobox_drug dbt:Pharma-stub dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Use_American_English dbt:Use_dmy_dates |
| dct:subject |
dbc:Copper_complexes dbc:DOTA_(chelator)_derivatives dbc:Radiopharmaceuticals dbc:Orphan_drugs |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
Copper (64Cu) oxodotreotide or Copper Cu 64 dotatate, sold under the brand name Detectnet, is a radioactive diagnostic agent indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults. Common side effects include nausea, vomiting and flushing. It was approved for medical use in the United States in September 2020. (en) |
| rdfs:label |
(64Cu)-oxodotreotid (cs) Copper (64Cu) oxodotreotide (en) |
| owl:sameAs |
wikidata:Copper (64Cu) oxodotreotide dbpedia-cs:Copper (64Cu) oxodotreotide https://global.dbpedia.org/id/FVdzo |
| prov:wasDerivedFrom |
wikipedia-en:Copper_(64Cu)_oxodotreotide?oldid=1120345182&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Copper_(64Cu)_oxodotreotide.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:Copper_(64Cu)_oxodotreotide |
| is dbo:wikiPageRedirects of |
dbr:Copper_Cu_64_dotatate dbr:Detectnet |
| is dbo:wikiPageWikiLink of |
dbr:Copper_Cu_64_dotatate dbr:Detectnet dbr:DOTA-TATE |
| is rdfs:seeAlso of |
dbr:Copper-64 |
| is foaf:primaryTopic of |
wikipedia-en:Copper_(64Cu)_oxodotreotide |
